An interventional study of Breath analysis and Blood analysis in Esophageal Cancer, Gastric Cancer and Barrett Esophagus, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by KU Leuven · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Esophageal Neoplasms with a site in Belgium — 17 open to participants now, 22 under way, 5 of them phase 3. Esophageal Neoplasms · Belgium.
Among the 41 studies in Esophageal Neoplasms with a site in Belgium, this one is the 3rd largest by planned enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2024, is one of 11 with no phase, reaches primary completion later than 17 of the 21 other live ones, and was the 36th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →17 of the 41 studies in Esophageal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Belgium, United States, Australia and 21 more countries
Ages 18+
University Hospital, Antwerp · Sites in Belgium, Denmark, France and 3 more countries
Ages 18+
KU Leuven · Sites in Belgium
Ages 18+
Radboud University Medical Center · Sites in Belgium, Netherlands
Ages 18+
KU Leuven · Sites in Belgium
Ages 18–85 · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 8 · Phase 3 7
First in 2002; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 58 across 1,347 interventional studies indexed under Esophageal Neoplasms.
Median enrollment 198 across the 32 interventional studies, 787 across the 8 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 41 have an industry lead sponsor. The 10 most frequent:
KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.
KU Leuven has 3 studies filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Esophageal Neoplasms with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT05688176University Hospital, GhentBarrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers | 2027-01-31 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 41 studies in Esophageal Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer.
The main questions this study aims to answer:
Are oncometabolites proficient and reproducible enough to function as diagnostic biomarkers? Can these biomarkers identify early-stage gastro-esophageal cancer? Researchers will compare participants with gastro-oesophageal cancer to healthy controls and participants with Barrett's esophagus to detect meaningful differences between the groups.
Participants will provide a breath and blood sample during their routine standard of care visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient has history of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with gastroesophageal cancer providing a breath and blood sample for biomarker identification
Diagnostic Test: Breath analysis · Diagnostic Test: Blood analysis
Participants with Barrett's esophagus providing a breath and blood sample for biomarker identification
Diagnostic Test: Breath analysis · Diagnostic Test: Blood analysis
Healthy controls providing a breath and blood sample for biomarker identification
Diagnostic Test: Breath analysis · Diagnostic Test: Blood analysis
Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath
Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood
Identification of the concentrations of oncometabolites
Identify the concentrations of cancer-related metabolites (oncometabolites) in the exhaled breath and blood compared to healthy controls
Time frame: year 1-2
Assessment of incidence of early-stage cancer
Distinguish early-stage gastro-oesophageal cancer from Barrett's esophagus and healthy controls based on sensitivity, specificity and accuracy of the oncometabolite concentration
Time frame: year 2-5
Assessment of incidence of therapy response
Predict and assess therapy response prior to surgery, based on sensitivity, specificity and accuracy of the oncometabolite concentration
Time frame: year 2-5
Assessment of percentage change of therapy response
Assess changes in the concentrations of the oncometabolites related to treatment.
Time frame: year 2-5
Assessment of incidence of recurrence
Predict and assess recurrence, based on sensitivity, specificity and accuracy of the oncometabolite concentration
Time frame: year 2-5
Plan to share: Yes — Data will be shared upon reasonable request with the principal investigator.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Jul 2029, 59 months after the start.
Of 209 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 94. This study's planned 59 months is above that.
Counting every sponsor, half of 218 studies reached it within 46 months; a quarter within 23 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.